AtriCure develops medical devices for the treatment of atrial fibrillation and related cardiac conditions. Its portfolio includes surgical ablation systems and left atrial appendage management products such as the AtriClip, used by cardiac surgeons and electrophysiologists. The company serves hospitals and surgical teams seeking specialized tools for rhythm control and stroke-risk reduction in open-heart and minimally invasive settings.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 136.1 | — | -6.2 | — |
| Q3 2025 | 134.3 | — | -0.3 | — |
| Q4 2025 | 140.5 | — | 1.8 | — |
| Q1 2026 | 141.3 | — | 0.1 | — |
| Q2 2026 | 153.6 | 12.8% | 9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: The Marzetti Company (MZTI), Kyivstar Group Ltd. (KYIV), Ionic Digital Inc. (IOND), Alarm.com Holdings, Inc. (ALRM), Denali Therapeutics Inc. (DNLI), Parabilis Medicines, Inc. (PBLS)